secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biofrontera Inc. (BFRI)
CIK:        0001858685
Form:       8-K
Filed at:   2026-02-09T23:59:59+00:00
Accession:  0001493152-26-005717
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biofrontera Phase 3 Ameluz® PDT meets primary endpoint for AK on extremities/neck/trunk
--------------------------------------------------------------------------------

- Complete clearance 45.6% (Ameluz®) vs 16.7% (vehicle), p<0.0003 in FAS.
- Per protocol set complete clearance 53.2% vs 22.2% (p<0.001).
- Study enrolled 172 patients randomized 4:1; lesion clearance rate 73.1% (FAS).
- Cosmetic outcomes: 75.2% rated 'good/very good'; 86.3% would choose PDT again.
- sNDA submission to FDA planned for Q3 2026 based on these positive results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858685/000149315226005717/0001493152-26-005717-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858685/000149315226005717/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-005717

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer